CERTERRA
Certerra – High resolution research solutions.
Certerra has developed a unique whole-brain assay to screen drugs for neuropsychiatric and neurological disorders.
Our difference
Whole-brain Pharmacomapping equals better CNS drug discovery.
We aim to radically improve predictability from preclinical studies to clinical trials. Certerra’s drug-screening method, called “pharmacomapping”, combines cutting-edge brain imaging and sophisticated statistical analyses to quantify drug-evoked brain activation at cellular resolution in animal models.
Delineating
For any given drug, Certerra’s process generates a map of whole-brain drug-evoked activation (or inhibition) in the animal model i.e., a whole-brain map “Pharmacomap™”.
Focusing
Certerra offers pharmacomapping as a CRO to a broad spectrum of pharmaceutical companies developing treatments for neurodevelopmental, psychiatric, and neurodegenerative disorders.
Our central hypothesis is that the effects a drug has are largely determined by which neurons it activates. Thus, we assert that CNS clinical trial unpredictability is in large part due to the lack of methods for mapping these relationships. We have bridged this gap by developing an automated Pharmacomap platform that allows us to visualize and then quantify drug-evoked brain activation at single-neuron resolution.
Why Pharmacomapping?
Our services
Our Services Include:
Pharmacomapping Level I
Drug-evoked brainwide c-fos mapping in naive mice, acute or chronic protocols.
Pharmacomapping Level II
Computational comparisons to a proprietary Clinical Pharmacomap Library of FDA-approved drugs.
Pharmacomapping Level III
Brainwide c-fos mapping in conjunction with disease-relevant mouse behaviors.
Alzheimer’s mouse models
Brainwide mapping of beta amyloid or other AD pathology.
Pharmacomapping in Alzheimer’s mouse models
Brainwide c-fos mapping in conjunction with beta amyloid mapping.
Custom assays
Possibility to develop custom assays with a broad range of IHC-compatible antibodies.